ArticleOncology letters2026
Identification of neoadjuvant chemoradiotherapy resistance-associated proteins in locally advanced rectal cancer: A pilot study.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemoradiotherapy (nCRT) resistance in locally advanced rectal cancer (LARC) leads to worse outcomes. The present pilot study aimed to identify candidate proteins associated with resistance to nCRT. Data-independent acquisition mass spectrometry on 15 formalin-fixed paraffin-embedded tumor tissues, collected before and after nCRT, from four nCRT-resistant and four nCRT-sensitive LARC cases, was performed, identifying 6,006 proteins. Before nCRT, 133 proteins were found to be more abundant in resistant tumors and were preliminarily enriched in cell junction and metabolic pathways. After nCRT, 290 proteins were found to be more abundantly expressed in resistant tumors and were preliminarily enriched in pathways associated with DNA replication, transcription, translation and metabolism. Combined analysis of datasets GSE209746 and PXD060201 prioritized branched-chain keto acid dehydrogenase E1 subunit α (BCKDHA) as a candidate resistance-associated protein. In a colorectal cancer (CRC) tissue microarray, upregulated BCKDHA expression was associated with shorter overall survival, supporting its broader clinical relevance in CRC. In SW480 cells, BCKDHA overexpression increased clonogenic survival following irradiation, whereas BCKDHA knockdown enhanced radiosensitivity. These changes were accompanied by altered ataxia telangiectasia mutated, checkpoint kinase 2, DNA repair protein RAD51 homolog 1-associated signaling and γ-H2A histone family member X dynamics after irradiation. Collectively, these data identified BCKDHA as a candidate nCRT resistance-associated protein in LARC and provided preliminary functional evidence associating BCKDHA with the response to radiotherapy and DNA damage response-associated signaling. Further validation in larger pretreatment LARC cohorts and more direct mechanistic studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.